Ongoing support to help start and stay on PLUVICTO treatment
Once you and your health care provider decide to begin PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), Novartis Patient Support is here to help.
Once you and your health care provider decide to begin PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), Novartis Patient Support is here to help.
*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare, Medicaid, or any other federal or state program. Offer subject to a maximum benefit per course of treatment. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms and Conditions in the enrollment forms for details.
What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...
What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...